On the evening of April 7, 2024, HealthGen announced its 2024 annual report, achieving an annual revenue of 15.619 billion yuan, a net profit attributable to shareholders of 1.387 billion yuan, a non-net profit attributable to shareholders of 1.319 billion yuan, and a net cash flow from operating activities of 3.636 billion yuan.

From the perspective of revenue structure, HealthGen has established an advantage in the respiratory field. Since the launch of the company's first high-end inhalation preparation in 2019, respiratory products have achieved a 22-fold increase in four years. In the past two years, the company has further expanded its innovative drug pipeline in the respiratory field around a clear strategic thinking. Among them, the phase III clinical trial of the innovative influenza drug "Mapasiv" has reached the primary endpoint, and the National Medical Products Administration has accepted the marketing application of the drug in August 2024. Currently, HealthGen has more than 10 innovative drugs for respiratory diseases, accelerating clinical advancement.

HealthGen stated that the company has not only honed its internationally leading respiratory preparation production technology over the past few years, but has also deployed an innovative pipeline covering the entire cycle of respiratory diseases. This is our core advantage in global competition. HealthGen will adhere to the vision of "carefully making good medicines and new drugs," cultivate the respiratory field, and accelerate the development of innovative drugs with global competitiveness.

Several innovative drugs in the respiratory field have achieved milestone breakthroughs.

Respiratory diseases, as a major global public health challenge, continue to increase the disease burden due to high prevalence, an aging population, and environmental pollution. In 2024, HealthGen's leading advantage in the respiratory field has been further highlighted.

As of the end of the reporting period, HealthGen's R&D pipeline in the respiratory field has covered more than 10 Class 1 innovative drugs, achieving full coverage of inhalation, oral, and injection dosage forms. Moreover, many core products have achieved milestone breakthroughs, driving a comprehensive upgrade in the respiratory disease treatment field through differentiated innovation.

Among them, Mapasiv, the fastest-progressing new anti-influenza drug, has completed Phase III clinical trials. HealthGen stated that the clinical results fully demonstrate the drug's excellent therapeutic effect, which can effectively shorten the course of influenza in patients. Mapasiv also exhibits three clinical characteristics: faster relief for influenza B, faster relief of symptoms for adolescent influenza patients, and prolonged virus suppression, requiring only a single dose.

In addition, for chronic obstructive pulmonary disease (COPD), a global challenge in the respiratory field, HealthGen is also actively deploying multiple first-in-class (FIC) drugs, including PREP inhibitors.

The annual report mentions that TSLP monoclonal antibody and IL-4R monoclonal antibody have both entered Phase II clinical research. Among them, TSLP monoclonal antibody, targeting moderate to severe COPD, shows particularly outstanding efficacy in populations with high levels of eosinophils. The company, with its first-mover advantage, is at the forefront of domestic pharmaceutical companies in terms of R&D progress.

In order to solve the compliance problem of existing inhaled drugs, the PREP-targeted COPD oral drug jointly developed by HealthGen and Bayer inhibits prolyl endopeptidase (PREP) activity through a unique mechanism of action, effectively controlling inflammatory responses, bringing effective treatment while significantly reducing the risk of adverse reactions, and effectively delaying disease progression. This drug is also the world's first COPD oral drug PREP inhibitor, and its Phase I clinical trial was rapidly launched in January 2025.

HealthGen stated that the company is determined to cultivate the respiratory field, aiming to become the "leading respiratory innovative drug company" in the Chinese A-share market.

Actively embracing AI technology to reshape the efficiency of various business segments.

After the 2025 Spring Festival, the major breakthroughs of generative large models such as Deepseek accelerated the landing speed of AI medical care, and HealthGen, which is in the transformation period, is also actively embracing AI technology.

HealthGen stated that the company started to vigorously promote the innovative application of AI technology in various business segments of the company as early as the beginning of 2024, accelerating the intelligent and digital transformation process of internal processes, and has achieved significant results.

For example, in the field of innovative drug R&D, the company uses world-leading AI models to comprehensively improve R&D efficiency, shorten the R&D cycle, and accelerate the listing process of innovative drugs in various aspects such as target identification, molecular design, and molecular screening. Recently, the company has also completed the deployment and application of the "full-blood" version of DeepSeek-R1 671B, becoming one of the first pharmaceutical companies in China to introduce AI models with hundreds of billions of parameters into its core business.

"We believe that with the rapid development of AI technology, AI will inevitably play an increasingly important role in all aspects of innovative drug R&D, production, and sales." HealthGen personnel gave an example: in molecular discovery, it used to be necessary to find molecules for a series of verifications, but now AI can combine past databases to build large models for drug development, design new drug molecules, and screen out molecules with low success rates. In the production and sales of raw materials and health products, efficiency can also be improved through intelligent sales management platforms. In the past two years, AI has also been used to strengthen online marketing, and the sales of star products such as Yingpai American Ginseng have shown immediate results.

Looking to the future, the global pharmaceutical industry is undergoing unprecedented changes in a century. On the one hand, the deep integration of AI technology and life sciences is reshaping the paradigm of drug development, bringing unlimited possibilities for breakthrough therapies; on the other hand, Chinese innovative pharmaceutical companies, with solid clinical data and differentiated innovation capabilities, are accelerating their journey to the center of the global stage. As a pioneer in innovative drugs in the respiratory field in China, HealthGen has already occupied a favorable position in this transformation.


This article is reproduced from: Every day Economic News